^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    elritercept (KER-050)

    i
    Other names: KER-050, KER 050, RKER-050, HS-20106, TAK-226, TAK226, TAK 226
    Associations

    News

    Trials
    Company:
    Jiangsu Hansoh Pharma, Keros Therap, Takeda
    Drug class:
    TGFβ inhibitor, Activin A inhibitor, Activin B inhibitor, GDF11 inhibitor, Myostatin inhibitor
    Related drugs:
    Associations

    News

    Trials
    7d
    ELRISE MF: A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib (clinicaltrials.gov)
    P3, N=324, Not yet recruiting, Takeda
    New P3 trial
    |
    Jakafi (ruxolitinib) • elritercept (KER-050)
    1m
    Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors. (PubMed, Expert Opin Pharmacother)
    Unmet needs include standardized endpoints, biologically stratified trials, and validation of hemoglobin and transfusion responses as markers. Strategies like momelotinib plus luspatercept, earlier intervention, and new molecular therapies could turn treatment from palliation to durable control and disease modification.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Xpovio (selinexor) • Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib) • pelabresib (DAK539) • elritercept (KER-050)
    1m
    A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (clinicaltrials.gov)
    P3, N=225, Recruiting, Takeda | N=82 --> 225
    Enrollment change
    |
    elritercept (KER-050)
    1m
    ELRiSE MDS: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (clinicaltrials.gov)
    P3, N=300, Recruiting, Takeda | N=84 --> 300
    Enrollment change • Trial initiation date
    |
    elritercept (KER-050)
    2ms
    ELRiSE MDS: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (clinicaltrials.gov)
    P3, N=51, Recruiting, Takeda
    New P3 trial
    |
    elritercept (KER-050)
    2ms
    TAK-226-3001: A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-nave adults who require RBC transfusions (2025-523544-12-00)
    P2/3, N=16, Not yet recruiting, Takeda Development Center Americas Inc.
    New P2/3 trial
    |
    elritercept (KER-050)
    3ms
    ELRiSE MDS: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (clinicaltrials.gov)
    P3, N=300, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    elritercept (KER-050)
    4ms
    ELRiSE MDS: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Takeda
    New P3 trial
    |
    elritercept (KER-050)
    5ms
    A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Takeda
    New P2 trial
    |
    elritercept (KER-050)
    7ms
    KER050-MD-201: A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, Takeda | Trial completion date: Oct 2030 --> Oct 2031
    Trial completion date
    |
    elritercept (KER-050)
    7ms
    RESTORE: A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis (clinicaltrials.gov)
    P2, N=135, Recruiting, Takeda | Trial completion date: Jan 2029 --> Feb 2030 | Trial primary completion date: Dec 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • elritercept (KER-050)
    9ms
    KER050-MD-201: A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=140, Recruiting, Takeda | Trial completion date: Nov 2025 --> Oct 2030 | Trial primary completion date: Jun 2025 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    elritercept (KER-050)